Antagonists of interleukin-2 receptor
US-9428567-B2 · Aug 30, 2016 · US
Immunostimulating IL-2 analogs
US11746137B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11746137-B2 |
| Application number | US-202117915808-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2021 |
| Priority date | Mar 31, 2020 |
| Publication date | Sep 5, 2023 |
| Grant date | Sep 5, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.
First claim
Opening claim text (preview).
The invention claimed is: 1. An interleukin-2 analog comprising any one sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 22, 53, 87, 89, 91, 99, 104, 105, and 106.
Assignees
Inventors
Classifications
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Interleukin · CPC title
- C12N15/70Primary
Vectors or expression systems specially adapted for E. coli · CPC title
- C07K14/55Primary
IL-2 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11746137B2 cover?
- The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.
- Who is the assignee on this patent?
- Hanmi Pharm Ind Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N15/70. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).